Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 1
2007 1
2008 1
2013 1
2016 1
2017 2
2018 2
2019 2
2020 3
2021 5
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
McCrimmon RJ, Al Sifri S, Emral R, Mohan V, Sauque-Reyna L, Trescolí C, Lalic N, Alvarez A, Demil N, Coudert M, Shaunik A, Bonnemaire M, Rosenstock J; SoliMix Trial investigators. McCrimmon RJ, et al. Among authors: bonnemaire m. Diabetes Obes Metab. 2021 Jun;23(6):1221-1231. doi: 10.1111/dom.14354. Epub 2021 Apr 29. Diabetes Obes Metab. 2021. PMID: 33606908 Clinical Trial.
Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
Rosenstock J, Emral R, Sauque-Reyna L, Mohan V, Trescolí C, Al Sifri S, Lalic N, Alvarez A, Picard P, Bonnemaire M, Demil N, McCrimmon RJ; SoliMix Trial Investigators. Rosenstock J, et al. Among authors: bonnemaire m. Diabetes Care. 2021 Jun 28;44(10):2361-70. doi: 10.2337/dc21-0393. Online ahead of print. Diabetes Care. 2021. PMID: 34183429 Free PMC article.
Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease: A REALI European Pooled Data Analysis.
Mauricio D, Gourdy P, Bonadonna RC, Freemantle N, Bigot G, Mauquoi C, Ciocca A, Bonnemaire M, Müller-Wieland D. Mauricio D, et al. Among authors: bonnemaire m. Diabetes Ther. 2021 Apr;12(4):1159-1174. doi: 10.1007/s13300-021-01031-z. Epub 2021 Mar 9. Diabetes Ther. 2021. PMID: 33751403 Free PMC article.
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, Berthou B, Pilorget V, Westerbacka J, Bosnyak Z, Bonnemaire M, Cali AMG, Nguyên-Pascal ML, Penfornis A, Perez-Maraver M, Seufert J, Sullivan SD, Wilding J, Wysham C, Davies M. Freemantle N, et al. Among authors: bonnemaire m. Curr Med Res Opin. 2020 Apr;36(4):571-581. doi: 10.1080/03007995.2019.1708287. Epub 2020 Jan 19. Curr Med Res Opin. 2020. PMID: 31865758 Free article. Clinical Trial.
Rationale and methodology for a European pooled analysis of postmarketing interventional and observational studies of insulin glargine 300 U/mL in diabetes: protocol of REALI project.
Freemantle N, Bonadonna RC, Gourdy P, Mauricio D, Mueller-Wieland D, Bigot G, Ciocca A, Mauquoi C, Rollot M, Bonnemaire M. Freemantle N, et al. Among authors: bonnemaire m. BMJ Open. 2020 Apr 28;10(4):e033659. doi: 10.1136/bmjopen-2019-033659. BMJ Open. 2020. PMID: 32350009 Free PMC article.
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer SA, Bonnemaire M, Sawhney S, Stewart J, Wang S, Castro RC, Garg SK. Danne T, et al. Among authors: bonnemaire m. Diabetes Technol Ther. 2019 Sep;21(9):471-477. doi: 10.1089/dia.2019.0157. Diabetes Technol Ther. 2019. PMID: 31335194 Free PMC article. Clinical Trial.
18 results